TFS Capital’s Voyager Therapeutics VYGR Stock Holding History

TFS Capital’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-29,468	Closed	-$324K	–	999
2016 Q2	$324K	Buy	+29,468	New	+$361K	0.06%	572

Other funds holding VYGR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TFS Capital's VYGR Position: Q3 2016 in Review

TFS Capital sold out of Voyager Therapeutics (VYGR) in Q3 2016, closing a stake of 29,468 shares — an estimated $324K sold.

TFS Capital first reported a position in VYGR in Q2 2016 and held it in 1 quarter. The position peaked at $324K in Q2 2016. 52 funds tracked by Wall St. Rank hold VYGR as of Q3 2016.

TFS Capital reported no remaining Voyager Therapeutics position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 29,468 Voyager Therapeutics shares in Q3 2016, an estimated $324K.
TFS Capital first reported a position in Voyager Therapeutics in Q2 2016 and held it in 1 quarter.
TFS Capital's Voyager Therapeutics position peaked at $324K in Q2 2016.
52 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.